ES2058169T3 - Enkastinas: nuevas glicopeptidos con efecto inhibidor de la encefalinasa, procedimiento para su preparacion y su empleo como preparados farmaceuticos. - Google Patents

Enkastinas: nuevas glicopeptidos con efecto inhibidor de la encefalinasa, procedimiento para su preparacion y su empleo como preparados farmaceuticos.

Info

Publication number
ES2058169T3
ES2058169T3 ES88106354T ES88106354T ES2058169T3 ES 2058169 T3 ES2058169 T3 ES 2058169T3 ES 88106354 T ES88106354 T ES 88106354T ES 88106354 T ES88106354 T ES 88106354T ES 2058169 T3 ES2058169 T3 ES 2058169T3
Authority
ES
Spain
Prior art keywords
rest
encephalinase
neutral
amino acid
enkastinas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88106354T
Other languages
English (en)
Inventor
Laszlo Dr Vertesy
Peter Dr Schindler
Herbert Dr Kogler
Hans-Wolfram Dr Fehlhaber
Francoise Delevallee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19873713873 external-priority patent/DE3713873A1/de
Priority claimed from DE19873739376 external-priority patent/DE3739376A1/de
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2058169T3 publication Critical patent/ES2058169T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C12R2001/47—Streptomyces albus

Abstract

LA INVENCION SE REFIERE A NUEVOS GLICOPEPTIDOS BIOLOGICAMENTE ACTIVOS DE FORMULA (I) DONDE SACCH REPRESENTA UN RESTO DE MONOSACARIDO, CON GRUPOS OH OPCIONALMENTE SUSTITUIDOS EN FORMA PARCIAL O TOTAL, A ES UN RESTO DE UN AMINOACIDO NEUTRO L O D, O, EN CASO DE FACTOR B, ES UN RESTO DE UN D-AMINOACIDO NEUTRO, B FALTA O ES UN RESTO DE AMINOACIDO NEUTRO L O D O UN AMINOACIDO ACIDO O BASICO L O D BIFUNCIONAL, OPCIONALMENTE OMEGA-SUSTITUIDO Y R REPRESENTA HIDROXI, ALCOXI C1-C8, UN RESTO AMINO, OPCIONALMENTE SUSTITUIDO CON UNO O DOS RESTOS IGUALES O DIFERENTES DE LA SERIE ALQUILO C1-C8, CICLOALQUILO C5-C8 O HETEROARILO, U OTRO DERIVADO DE ACIDO. ESTOS COMPUESTOS POSEEN PROPIEDADES INHIBIDORAS DE LA ENCEFALINASA Y POR ELLO PUEDEN EMPLEARSE P.E. COMO ANALGESICOS EN MEDICINA Y VETERINARIA. SE DESCRIBE ADEMAS EL AISLAMIENTO DE ESTOS COMPUESTOS A PARTIR DE STREPTOMYCES ALBUS ATCC 21838 ASI COMO OTROS PROCEDIMIENTOS PARA SU OBTENCION.
ES88106354T 1987-04-25 1988-04-21 Enkastinas: nuevas glicopeptidos con efecto inhibidor de la encefalinasa, procedimiento para su preparacion y su empleo como preparados farmaceuticos. Expired - Lifetime ES2058169T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873713873 DE3713873A1 (de) 1987-04-25 1987-04-25 Enkastine: neue glycopeptide mit enkephalinase-hemmender wirkung, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutische praeparate
DE19873739376 DE3739376A1 (de) 1987-11-20 1987-11-20 Enkastine: neue glycopeptide mit enkephalinase-hemmender wirkung, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutische praeparate

Publications (1)

Publication Number Publication Date
ES2058169T3 true ES2058169T3 (es) 1994-11-01

Family

ID=25854960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88106354T Expired - Lifetime ES2058169T3 (es) 1987-04-25 1988-04-21 Enkastinas: nuevas glicopeptidos con efecto inhibidor de la encefalinasa, procedimiento para su preparacion y su empleo como preparados farmaceuticos.

Country Status (15)

Country Link
US (1) US5302582A (es)
EP (1) EP0288897B1 (es)
JP (1) JP2610646B2 (es)
KR (1) KR880012643A (es)
CN (1) CN1030766A (es)
AU (1) AU607486B2 (es)
DE (1) DE3883055D1 (es)
DK (1) DK222488A (es)
ES (1) ES2058169T3 (es)
FI (1) FI881869A (es)
HU (1) HU198953B (es)
IL (1) IL86168A (es)
NO (1) NO172351C (es)
NZ (1) NZ224341A (es)
PT (1) PT87306B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE184611T1 (de) * 1991-11-29 1999-10-15 Hoechst Ag Peptide mit insulinartiger wirkung
US5679769A (en) * 1994-03-15 1997-10-21 Sloan-Kettering Institute For Cancer Research Synthesis of asparagine-linked glycopeptides on a polymeric solid support
DK1216707T3 (da) * 2000-12-22 2005-05-09 Pasteur Institut Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet
CN100412082C (zh) * 2003-10-16 2008-08-20 北京北医投资管理有限公司医药科技开发分公司 环糖基氨基酸及其制备方法和防治重金属中毒的用途
JP4616928B2 (ja) * 2003-11-19 2011-01-19 花王株式会社 フルクトシルジペプチド又はその塩
JP4542874B2 (ja) * 2003-11-19 2010-09-15 花王株式会社 フルクトシルジペプチド又はその塩
JP4589823B2 (ja) * 2005-06-22 2010-12-01 花王株式会社 化粧料
JP4589824B2 (ja) * 2005-06-22 2010-12-01 花王株式会社 化粧料
JP4584784B2 (ja) * 2005-06-22 2010-11-24 花王株式会社 化粧料
CN101285046B (zh) * 2007-04-09 2011-08-17 天津科技大学 一种诱变菌株白色链霉菌TUST2及利用该诱变菌株生产ε-聚赖氨酸及其盐的方法

Also Published As

Publication number Publication date
NO172351B (no) 1993-03-29
HU198953B (en) 1989-12-28
NO881778L (no) 1988-10-26
JPS63295598A (ja) 1988-12-01
KR880012643A (ko) 1988-11-28
PT87306A (pt) 1988-05-01
NO881778D0 (no) 1988-04-22
DE3883055D1 (de) 1993-09-16
CN1030766A (zh) 1989-02-01
FI881869A (fi) 1988-10-26
NZ224341A (en) 1991-05-28
US5302582A (en) 1994-04-12
EP0288897A2 (de) 1988-11-02
PT87306B (pt) 1992-08-31
NO172351C (no) 1993-07-07
AU1509888A (en) 1988-10-27
AU607486B2 (en) 1991-03-07
EP0288897A3 (de) 1991-02-27
JP2610646B2 (ja) 1997-05-14
IL86168A0 (en) 1988-11-15
DK222488A (da) 1988-10-26
HUT47600A (en) 1989-03-28
DK222488D0 (da) 1988-04-22
FI881869A0 (fi) 1988-04-21
EP0288897B1 (de) 1993-08-11
IL86168A (en) 1993-04-04

Similar Documents

Publication Publication Date Title
ES2058169T3 (es) Enkastinas: nuevas glicopeptidos con efecto inhibidor de la encefalinasa, procedimiento para su preparacion y su empleo como preparados farmaceuticos.
KR890001572A (ko) 표유동물에게 히알우론산을 원격 투여하는 방법
NZ330369A (en) aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester
UA26324A (uk) Спосіб одержаhhя біологічhо активhої композиції
BR9707958A (pt) Composto, composição farmacêutica, e, processo para tratar hiperalgesia em um paciente.
ES2179929T3 (es) Procedimiento que trata de inhibir la osteolisis y las metastasis.
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
MY103746A (en) Improvements in or relating to somatostatins
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BRPI0405657A (pt) Método para o tratamento de insuficiência cardìaca grave e medicamento para o mesmo
JPS57131759A (en) 2-oxoazetidine derivative, its preparation and use
ES2087280T3 (es) 4-fenil-4-piperidina-carboxamidas sustituidas con efecto tanto anestesico local como analgesico, asi como procedimientos para su preparacion.
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
BR9106676A (pt) Peptideo,processo para promover a liberacao de niveis de hormonio de crescimento em um animal,composicao farmaceutica para promover a liberacao de niveis de hormonio de crescimento em animais,uso do composto e processo para promover a liberacao e elevacao de niveis de hormonio de crescimento no sangue
IE894050L (en) Compound with gastric acid inhibitory effect and process for¹its preparation
IL126175A (en) Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists
HUP9801712A2 (hu) Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása
NO932722L (no) Salter av et 4-amino-3acyl-kinolinderivat og deres anvendelse som inhibatorer for gastrisk syresekresjon
DE3574969D1 (de) Aetheroxidderivate von zyklopropylphenolen.
BR9911756A (pt) Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto
AU5198686A (en) Praparat zur intramuskularen injektion von medikamenten vitaminen oder impfstoffen
DE69414845D1 (de) Flüssigantazidzusammensetzungen
ES2170377T3 (es) Composicion que contiene quitosana.
PT98538A (pt) Processo de preparacao de factor de crescimento humano epidermico (hegf) dos seus congeneres e de composicoes farmaceuticas que os contem
Harvey et al. In vitro inhibition of lipopolysaccharide-induced bone resorption by polymyxin B.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 288897

Country of ref document: ES